Please Wait.....
Report
RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi), By Phase (Phase I, Phase II, Phase III, Phase IV), By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others), By Region, Competition, Forecast and Opportunities, 2028
Market Report (3 business days) I 2023-10-03 I 190 Pages I TechSci Research
The Global RNA Therapy Clinical Trials Market recorded a valuation of USD 2.62 Billion in 2022 and is expected to experience substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 5.06% and expected to reach USD 3.49 Billion through 2028. RNA therapy, a cutting-edge field of medical research, has emerged as a promising avenue for developing innovative treatments for a wide range of diseases. This novel approach harnesses the power of ribonucleic acid (RNA) to modulate gene expression and provide therapeutic benefits.
Market Overview:
The global RNA therapy clinical trials market has gained significant traction in recent years, revolutionizing the healthcare landscape and offering potential solutions for previously untreatable conditions. RNA therapy operates on the principle of utilizing RNA molecules, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), to target specific genes and regulate their activity. This precision-based approach holds immense potential for addressing genetic disorders, infectious diseases, cancer, and even rare conditions that lack effective treatment options. Unlike traditional pharmaceuticals, RNA therapies aim to intervene at the genetic level, potentially providing more targeted and personalized treatments.
Key Market Drivers:
1. Rapid Advancement in RNA Technology:
Rapid advances in RNA technology have significantly propelled the Global RNA Therapy Clinical Trials Market, revolutionizing the landscape of medical research and healthcare. These breakthroughs are driving the development of innovative RNA-based therapies with the potential to address a wide spectrum of diseases and conditions.
2. Success of mRNA Vaccines:
The resounding success of mRNA vaccines has reverberated across the Global RNA Therapy Clinical Trials Market, catalyzing a paradigm shift in medical research and therapeutic development. The unprecedented achievements of mRNA vaccines have illuminated the immense potential of RNA-based therapies and spurred accelerated advancements in the field.
3. Technological Innovation:
Technological innovation stands as a driving force within the Global RNA Therapy Clinical Trials Market, ushering in transformative advancements that are reshaping the landscape of medical research and therapeutic development. These innovations span a range of areas critical to the success of RNA-based therapies and hold the potential to overcome challenges, enhance efficacy, and accelerate the translation of cutting-edge science into tangible clinical applications.
Key Market Challenges:
1. Delivery Challenges:
Delivery challenges are a critical aspect of the Global RNA Therapy Clinical Trials Market, representing a complex hurdle that researchers and developers must overcome to ensure the safe and effective administration of RNA-based therapies. These challenges center around the successful and targeted delivery of RNA molecules to specific cells or tissues within the body, a fundamental requirement for achieving the desired therapeutic outcomes.
2. Stability and Half-Life:
Stability and half-life are crucial considerations in the Global RNA Therapy Clinical Trials Market, playing a pivotal role in determining the effectiveness, safety, and practicality of RNA-based therapies. These factors directly impact the therapeutic potential of RNA molecules and their ability to deliver sustained and desired outcomes.
Key Market Trends:
1. Personalized and Precision Medicine:
Personalized and precision medicine represents a transformative approach within the Global RNA Therapy Clinical Trials Market, heralding a new era of tailored treatments that leverage individual genetic information to enhance therapeutic efficacy and minimize adverse effects.
2. Gene Editing Integration:
Gene editing integration represents a groundbreaking frontier within the Global RNA Therapy Clinical Trials Market, where the convergence of RNA-based therapies and advanced gene editing technologies is unlocking new avenues for targeted and precise interventions at the genetic level.
Segmental Insights:
Modality Insights:
In 2022, the RNA Therapy Clinical Trials Market was dominated by the messenger RNA segment, primarily due to the use of mRNA-based vaccinations and their potential in various disease states.
Phase Insights:
In 2022, the RNA Therapy Clinical Trials Market was dominated by phase II clinical trials, as they play a crucial role in determining the ideal dose and dosing regimen for RNA therapies.
Regional Insights:
In 2022, North America led the RNA Therapy Clinical Trials Market due to early adoption, robust research infrastructure, a favorable regulatory environment, and a strong biotechnology and pharmaceutical industry.
In conclusion, the Global RNA Therapy Clinical Trials Market is poised for significant growth, driven by rapid advancements in RNA technology, the success of mRNA vaccines, and ongoing technological innovations. While challenges such as delivery and stability must be addressed, the integration of personalized medicine and gene editing holds promise for reshaping the landscape of medical care and treatment.
Key Market Players
- IQVIA
- ICON Plc
- Laboratory Corporation of America Holdings
- Charles River Laboratories International, Inc.
- PAREXEL International Corp.
- Syneos Health
- Medpace Holdings, Inc.
- Novotech
- Veristat, LLC.
- Veristat, LLC.
Report Scope:
In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
2. Global RNA Therapy Clinical Trials Market, By Modality:
- RNA interference
- Antisense therapy Messenger RNA
- Oligonucleotide
- Non-antisense
- Non-RNAi
3. Global RNA Therapy Clinical Trials Market, By Phase:
- Phase I
- Phase II
- Phase III
- Phase IV
4. Global RNA Therapy Clinical Trials Market, By Therapeutic Area:
- Rare Diseases
- Anti-infective
- Anticancer
- Neurological
- Alimentary/Metabolic
- Musculoskeletal
- Cardiovascular Respiratory
- Sensory
- Others
5. Global RNA Therapy Clinical Trials Market, By Region:
- North America
5...1. United States
5...2. Canada
5...3. Mexico
- Europe
5...1. Germany
5...2. France
5...3. United Kingdom
5...4. Italy
5...5. Spain
- Asia-Pacific
5...1. China
5...2. Japan
5...3. India
5...4. South Korea
5...5. Australia
5...6. Singapore
- South America
5...1. Brazil
5...2. Argentina
5...3. Colombia
- Middle East & Africa
5...1. UAE
5...2. Saudi Arabia
5...3. South Africa
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.
Available Customizations:
Global RNA Therapy Clinical Trials Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
6. Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Types
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global RNA Therapy Clinical Trials Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)
5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
5.2.3. By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)
5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.5. By Company (2022)
5.3. Product Market Map
5.3.1. By Modality
5.3.2. By Phase
5.3.3. By Therapeutic Areas
5.3.4. By Region
6. North America RNA Therapy Clinical Trials Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Modality
6.2.2. By Phase
6.2.3. By Therapeutic Areas
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States RNA Therapy Clinical Trials Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Modality
6.3.1.2.2. By Phase
6.3.1.2.3. By Therapeutic Areas
6.3.2. Canada RNA Therapy Clinical Trials Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Modality
6.3.2.2.2. By Phase
6.3.2.2.3. By Therapeutic Areas
6.3.3. Mexico RNA Therapy Clinical Trials Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Modality
6.3.3.2.2. By Phase
6.3.3.2.3. By Therapeutic Area
7. Europe RNA Therapy Clinical Trials Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Modality
7.2.2. By Phase
7.2.3. By Therapeutic Area
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany RNA Therapy Clinical Trials Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Modality
7.3.1.2.2. By Phase
7.3.1.2.3. By Therapeutic Area
7.3.2. France RNA Therapy Clinical Trials Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Modality
7.3.2.2.2. By Phase
7.3.2.2.3. By Therapeutic Area
7.3.3. United Kingdom RNA Therapy Clinical Trials Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Modality
7.3.3.2.2. By Phase
7.3.3.2.3. By Therapeutic Area
7.3.4. Italy RNA Therapy Clinical Trials Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Modality
7.3.4.2.2. By Phase
7.3.4.2.3. By Therapeutic Area
7.3.5. Spain RNA Therapy Clinical Trials Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Modality
7.3.5.2.2. By Phase
7.3.5.2.3. By Therapeutic Area
8. Asia-Pacific RNA Therapy Clinical Trials Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Modality
8.2.2. By Phase
8.2.3. By Therapeutic Area
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China RNA Therapy Clinical Trials Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Modality
8.3.1.2.2. By Phase
8.3.1.2.3. By Therapeutic Area
8.3.2. Japan RNA Therapy Clinical Trials Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Modality
8.3.2.2.2. By Phase
8.3.2.2.3. By Therapeutic Area
8.3.3. India RNA Therapy Clinical Trials Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Modality
8.3.3.2.2. By Phase
8.3.3.2.3. By Therapeutic Area
8.3.4. South Korea RNA Therapy Clinical Trials Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Modality
8.3.4.2.2. By Phase
8.3.4.2.3. By Therapeutic Area
8.3.5. Australia RNA Therapy Clinical Trials Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Modality
8.3.5.2.2. By Phase
8.3.5.2.3. By Therapeutic Area
9. South America RNA Therapy Clinical Trials Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Modality
9.2.2. By Phase
9.2.3. By Therapeutic Area
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil RNA Therapy Clinical Trials Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Modality
9.3.1.2.2. By Phase
9.3.1.2.3. By Therapeutic Area
9.3.2. Argentina RNA Therapy Clinical Trials Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Modality
9.3.2.2.2. By Phase
9.3.2.2.3. By Therapeutic Area
9.3.3. Colombia RNA Therapy Clinical Trials Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Modality
9.3.3.2.2. By Phase
9.3.3.2.3. By Therapeutic Area
10. Middle East and Africa RNA Therapy Clinical Trials Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Modality
10.2.2. By Phase
10.2.3. By Therapeutic Area
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. UAE RNA Therapy Clinical Trials Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Modality
10.3.1.2.2. By Phase
10.3.1.2.3. By Therapeutic Area
10.3.2. Saudi Arabia RNA Therapy Clinical Trials Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Modality
10.3.2.2.2. By Phase
10.3.2.2.3. By Therapeutic Area
10.3.3. South Africa RNA Therapy Clinical Trials Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Modality
10.3.3.2.2. By Phase
10.3.3.2.3. By Therapeutic Area
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition
12.2. Product Development
12.3. Recent Developments
13. Clinical Trial Analysis
13.1. Ongoing Clinical Trials
13.2. Completed Clinical Trials
13.3. Terminated Clinical Trials
13.4. Breakdown of Pipeline, By Development Phase
13.5. Breakdown of Pipeline, By Status
13.6. Breakdown of Pipeline, By Study Type
13.7. Breakdown of Pipeline, By Region
13.8. Clinical Trials Heat Map
14. Competitive Landscape
14.1. Business Overview
14.2. Company Snapshot
14.3. Products & Services
14.4. Financials (As Reported)
14.5. Recent Developments
14.5.1. IQVIA
14.5.2. ICON Plc
14.5.3. Laboratory Corporation of America Holdings
14.5.4. Charles River Laboratories International, Inc.
14.5.5. PAREXEL International Corp.
14.5.6. Syneos Health
14.5.7. Medpace Holdings, Inc.
14.5.8. Novotech
14.5.9. Veristat, LLC.
14.5.10. Veristat, LLC.
15. Strategic Recommendations
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security